The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley ...
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths came ...
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results